Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114288

Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.

R A Liddle, B J Gertz, S Kanayama, L Beccaria, L D Coker, T A Turnbull, and E T Morita

Cell Biology Laboratory, Mount Zion Hospital and Medical Center, San Francisco, California 94115.

Find articles by Liddle, R. in: JCI | PubMed | Google Scholar

Cell Biology Laboratory, Mount Zion Hospital and Medical Center, San Francisco, California 94115.

Find articles by Gertz, B. in: JCI | PubMed | Google Scholar

Cell Biology Laboratory, Mount Zion Hospital and Medical Center, San Francisco, California 94115.

Find articles by Kanayama, S. in: JCI | PubMed | Google Scholar

Cell Biology Laboratory, Mount Zion Hospital and Medical Center, San Francisco, California 94115.

Find articles by Beccaria, L. in: JCI | PubMed | Google Scholar

Cell Biology Laboratory, Mount Zion Hospital and Medical Center, San Francisco, California 94115.

Find articles by Coker, L. in: JCI | PubMed | Google Scholar

Cell Biology Laboratory, Mount Zion Hospital and Medical Center, San Francisco, California 94115.

Find articles by Turnbull, T. in: JCI | PubMed | Google Scholar

Cell Biology Laboratory, Mount Zion Hospital and Medical Center, San Francisco, California 94115.

Find articles by Morita, E. in: JCI | PubMed | Google Scholar

Published October 1, 1989 - More info

Published in Volume 84, Issue 4 on October 1, 1989
J Clin Invest. 1989;84(4):1220–1225. https://doi.org/10.1172/JCI114288.
© 1989 The American Society for Clinical Investigation
Published October 1, 1989 - Version history
View PDF
Abstract

To explore the physiology of cholecystokinin (CCK) in humans, we investigated the effect on gallbladder contraction and gastric emptying of a recently developed CCK receptor antagonist, MK-329. In a double-blind, four-period crossover study eight subjects received single doses of 0.5, 2, or 10 mg MK-329, or placebo, followed by an intravenous infusion of CCK-8 (30 pmol/kg.h). In placebo-treated subjects gallbladder volumes decreased on average to 43% of initial volumes after 2 h of CCK infusion. MK-329 caused a dose-dependent inhibition of CCK-stimulated gallbladder contraction with 10 mg producing complete blockade (P less than 0.01, cf. placebo). Gallbladder contraction and gastric emptying rates after a mixed meal were then measured in a two-period crossover study. Subjects received placebo or 10 mg of MK-329 2 h before eating. Gastric emptying of both solids and liquids was measured simultaneously by gamma scintigraphy. In placebo-treated subjects plasma CCK levels increased postprandially to 2.3 pM, gallbladder volumes decreased 68.4 +/- 3.8% (SE), and the times for 50% emptying of liquids and solids from the stomach were 58 +/- 10 and 128 +/- 8 min, respectively. In MK-329-treated subjects there was a marked elevation in peak CCK levels to 13.8 pM (P less than 0.01, cf. placebo), and gallbladder contraction was completely inhibited. Solid and liquid emptying rates were unaffected. These findings demonstrate that (a) MK-329 is a potent, orally active antagonist of CCK in humans, and (b) CCK is the major regulator of postprandial gallbladder contraction. These data also support the concept of negative feedback regulation of CCK secretion and suggest that mechanisms other than CCK play a dominant role in the regulation of postprandial gastric emptying rates.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1220
page 1220
icon of scanned page 1221
page 1221
icon of scanned page 1222
page 1222
icon of scanned page 1223
page 1223
icon of scanned page 1224
page 1224
icon of scanned page 1225
page 1225
Version history
  • Version 1 (October 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts